Status:

COMPLETED

Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer

Lead Sponsor:

Asan Medical Center

Conditions:

Stage IV Gastric Cancer With Metastasis

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

A maximum of 8 cycles of chemotherapy will be administered. Depending on patients' tolerability, 8 cycles of chemotherapy will be given to the patients.

Detailed Description

Single-center, open-label, prospective, single-arm, phase I-II study About 37 patients (Phase I 18, Phase II 31 (including 12 patients from Phase I)

Eligibility Criteria

Inclusion

  • Unresectable or metastatic advanced gastric adenocarcinoma confirmed by histology
  • Peritoneal seeding proven by histology or cytology
  • Completion of adjuvant chemotherapy 6 months before the study, or no previous chemotherapy (But, patients who received docetaxel or cisplatin as adjuvant chemotherapy should be excluded)
  • Age 18 to 70 years old
  • Eastern Cooperative Oncology Group performance status \<\_ 2
  • Estimated life expectancy of more than 3 months
  • Adequate bone marrow function (WBCs\>3,000/µL and absolute neutrophil count (ANC) \>1,500/µL and platelets\>100,000/µL),
  • Adequate renal function: creatinine \< 1 x upper normal limit (UNL) or creatinine clearance \_\> 60ml/min
  • Adequate hepatic function: bilirubin \< 1.5 x UNL, AST/ALT levels \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL (except in case of bone metastasis without any liver disease)
  • Written informed consent

Exclusion

  • Contraindication to any drug contained in the chemotherapy regimen
  • Other tumor type than adenocarcinoma
  • Presence or history of CNS metastasis
  • Gastric outlet or bowel obstruction
  • Evidence of serious gastrointestinal bleeding
  • Peripheral neuropathy \> grade 2
  • History of significant neurologic or psychiatric disorders
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
  • Pregnant or lactating women, women of childbearing potential not employing adequate contraception
  • Other serious illness or medical conditions

Key Trial Info

Start Date :

February 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2014

Estimated Enrollment :

37 Patients enrolled

Trial Details

Trial ID

NCT01525771

Start Date

February 1 2011

End Date

December 1 2014

Last Update

June 29 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asan Medical Center

Seoul, South Korea